Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study
Open Access
- 22 December 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 16 (3), 311-320
- https://doi.org/10.1016/s1473-3099(15)00486-7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical TrialThe Journal of Infectious Diseases, 2014
- Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challengeNature Medicine, 2014
- Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine VectorsPLOS ONE, 2012
- Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine VectorThe Journal of Infectious Diseases, 2012
- Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in ManScience Translational Medicine, 2012
- Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple SpeciesScience Translational Medicine, 2012
- Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus ChallengeJournal of Virology, 2011
- A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adultsVaccine, 2010
- A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical TrialClinical and Vaccine Immunology, 2006
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNature, 2003